Akebia Therapeutics, Inc. AKBA
0.90
(0.02)
(2.17%)
as of 25 Sep
- Market cap
- $254.7M
- P/E
- 0.0×
Follow AKBA
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
| P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
| P/S ratio | 3.21 | 1.75 | 1.60 | 1.40 | |
| P/FCF ratio | 22.35 | 6.10 | 6.18 | 7.63 | |
| P/Operating CF | 25.72 | 13.30 | (17.50) | 87.19 | |
| P/B ratio | 17.38 | 12.70 | 13.56 | 12.29 | |
| Price to Tangible BV | 0.00 | 0.00 | 0.00 | 0.00 | |
| EV/Sales | 2.76 | 1.25 | 1.11 | 0.92 | |
| EV/EBITDA | 22.17 | 11.91 | 39.17 | 0.00 | |
| EV/Operating CF | 19.19 | 4.34 | 4.26 | 4.85 | |
| EV/FCF | 19.22 | 4.35 | 4.29 | 5.00 | |
| Quick Ratio | 1.74 | 1.42 | 1.30 | 1.30 | |
| Current Ratio | 1.94 | 1.55 | 1.40 | 1.43 | |
| Net Debt/EBITDA | (24.92) | 16.59 | 26.04 | 18.46 | |
| Debt/Assets | 13.08% | 12.81% | 13.49% | 14.17% | |
| Debt/Equity | 1.15 | 1.48 | 1.79 | 1.98 | |
| Asset Turnover | 0.79 | 0.79 | 0.69 | 0.63 | |
| Operating CF/Net income | 52.05 | (2.54) | 2.34 | (0.40) | |
| Capex/Depreciation | (0.24) | (0.22) | (0.19) | (1.84) | |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 | |
| Research and Development Expense of Revenue | 25.43% | 46.25% | 27.65% | 28.62% | |
| Selling, General and Administrative Expense of Revenue | 49.51% | 45.28% | 56.84% | 57.34% | |
| Intangible Assets out of Total Assets | 0.16 | 0.16 | 0.16 | 0.17 | |
| Share Based Compensation of Revenue | 5.48% | 5.55% | 6.85% | 6.57% | |
| Graham Net Nets | (0.09) | (0.22) | (0.25) | (0.31) | |
| Graham Number | 0.00 | 0.00 | 0.00 | 0.00 | |
| Earnings Yield | (2.46%) | (1.06%) | (5.55%) | (9.47%) | |
| Free Cash Flow Yield | 4.47% | 16.39% | 16.17% | 13.10% | |
| Revenue per Share | 0.22 | 0.22 | 0.20 | 0.18 | |
| Operating CF per Share | 0.11 | 0.12 | (0.08) | 0.01 | |
| Capex per Share | 0.00 | 0.00 | 0.00 | 0.00 | |
| Free Cash Flow per Share | 0.11 | 0.12 | (0.08) | 0.01 | |
| Cash per Share | 0.63 | 0.72 | 0.61 | 0.58 | |
| Shareholders Equity per Share | 0.16 | 0.13 | 0.10 | 0.09 | |
| Interest Debt per Share | 0.00 | 0.00 | 0.00 | 0.00 | |
| Book value per Share | 0.16 | 0.13 | 0.10 | 0.09 | |
| Free Cash Flow | 28.03 | 31.06 | (21.27) | 2.45 | |
| Working Capital | 124.96 | 90.02 | 69.60 | 68.69 | |
| Capital Expenditures | (0.08) | (0.07) | (0.06) | (1.08) | |
| Net Current Asset Value | (64.22) | (91.00) | (91.66) | (95.09) | |
| EV/EBIT | 35.03 | 12.55 | 48.67 | 0.00 | |
| Capex to Sales | 0.00 | 0.00 | 0.00 | 0.02 | |
| Net Profit Margin | 0.92% | (21.25%) | (16.91%) | (18.13%) | |
| Price to Operating Income | 40.73 | 17.62 | 70.18 | 0.00 | |
| Other line items | |||||
| Average Receivables | 49.20 | 40.70 | 62.04 | 63.16 | |
| Average Payables | 11.79 | 18.18 | 10.52 | 10.49 | |
| Average Inventory | 19.57 | 15.93 | 16.36 | 14.86 | |
| Average Assets | 285.65 | 298.62 | 336.35 | 347.63 | |
| Average Common Equity | (4.41) | (8.29) | 25.98 | 27.12 |
Columns are period end dates